Alcidion Group Limited · ASX:ALC
Alcidion — Investor Presentation (April 2021)
17 slides from Alcidion's investor presentation, Apr 15, 2021
Slide 1: Investor Presentation: Acquisition of ExtraMed
Investor Presentation Acquisition of ExtraMed Kate Quirke, Group Managing Director 15 April 2021 1
Slide 2: Executive Summary
Executive Summary Executing upon stated objectives with the aim of becoming a leading global healthcare organisation Acquisition of Preferred Supplier – 3 1 2 Capital Raising ExtraMed Limited Major Australian contract • Acquisition of ExtraMed, leading UK provider • Selected, as part of a Consortium
Slide 3: Strong Organic Growth + Outlook
Strong Organic Growth + Outlook Strong organic growth + ExtraMed acquisition continue to accelerate Alcidion’s recurring revenue profile, positioning the Company to be breakeven in FY2022 4 Continuing Organic Sales Momentum 5 Outlook • Contracted revenue for FY2021 stands at $24.7m at Q3 FY20211, •
Slide 4: ExtraMed Overview
ExtraMed Overview 4
Slide 5: ExtraMed Snapshot
ExtraMed Snapshot Long-standing UK market leader in patient flow, addressing key pain-points for hospital administrative staff Business Overview Pro Forma FY22 Forecast Contribution to Alcidion • Leading UK provider with a 20+ year track record providing patient • FY22 pro forma contribution based o
Slide 6: Established value with key NHS Trusts
Established value with key NHS Trusts Value Proposition for Hospitals ExtraMed Customer Overview Releases staff time for patient Care • 9 customers; all except one have been customer for >3.5 years 1 Improves handover and information sharing, providing better visibility of patient flow to increase e
Slide 7: Acquisition Rationale
Acquisition Rationale Aligned with Alcidion’s criteria for acquisitions • Access to 9 long-standing customers, with Alcidion currently having no presence with 6 customers Expanding UK • Expands UK market presence to 27 Trusts, implying an indicative market share of ~19%1 1 customer base • Provides f
Slide 8: Strong Organic Growth
Strong Organic Growth 8
Slide 9: Continuing to build sales momentum in Q3 FY2021
Continuing to build sales momentum in Q3 FY2021 Contracted revenue for FY2021 stands at $24.7m at Q31, adding $3.0m over the Qtr. ($21.7M at Q2 FY2021) UK Contracts & Extensions ANZ Contracts & Extensions • East Lancashire: 5-year, $2.2M TCV for Patientrack and Smartpage • Te Manawa Taki DHBs (NZ):
Slide 10: Preferred supplier for potential $21M contract
Preferred supplier for potential $21M contract Preferred party to major Australian Defence Force contract • Alcidion selected, as part of a Consortium, as preferred provider for major healthcare IT project to capture data and support clinical decision making across the Australian Defence Force – Con
Slide 11: Capital Raising
Capital Raising 11
Slide 12: Capital Raising – Details
Capital Raising – Details Transaction Overview Offer size A$17.9m, reflecting the issue of approximately 55.8 million shares • Placement to raise A$15.36m via the issue of approximately 48.0 million fully paid ordinary shares; and • Share Purchase Plan1 to raise A$2.5m via the issue of approximately
Slide 13: Capital Raising – Indicative Timetable
Capital Raising – Indicative Timetable1 Key Events Key Dates Trading halt (before market open) Wednesday, 14 April 2021 Placement bookbuild 14 April 2021 Record date for SPP 7:00pm (AEST) Wednesday, 14 April 2021 Announcement of the Placement + Trading halt lifted (before market open) Thursday, 15 A
Slide 14: Key Risks
Key Risks 1) Share market On completion of the Placement, the New Shares may trade on ASX at higher or lower prices than the issue price. Investors who decide to sell their New Shares after the Placement may not receive the amount of their original investment. The price at which the New Shares trade
Slide 15: Key Risks
Key Risks 4) Regulatory risk The Company operates in a highly regulated market both in Australia and internationally. Success can be impacted by changes to the regulatory environment. The Company continues to monitor changes and proposed changes to the regulatory environment to which it is exposed.
Slide 16: Disclaimer
Disclaimer The information contained in this document (“Document”) has been prepared by Alcidion Group Limited ACN 143 142 410 (referred to as “Alcidion” or “Company”). This Document is current as at the date of this Document and should be read in conjunction with other Alcidion periodic and continu
Slide 17: Slide 17